Ciba Health is a technology company.
Ciba Health has raised $10.0M across 1 funding round.
Ciba Health has raised $10.0M in total across 1 funding round.
Ciba Health has raised $10.0M in total across 1 funding round.
Ciba Health's investors include DigiTx Partners, Esplanade HealthTech Ventures, OCA Ventures.
Ciba Health is a New York-based digital health technology company founded in 2020 that builds an AI-powered virtual chronic care platform to prevent, manage, and reverse chronic diseases like type 2 diabetes, obesity, and autoimmune disorders.[1][2][3] It serves employers, health plans, health systems, and individual consumers (via its Thrive offering) by solving the problem of fragmented, symptom-focused care through root-cause medicine, multidisciplinary care teams, advanced lab testing (up to 300 biomarkers), predictive analytics, remote monitoring, nutrition coaching, and personalized plans that deliver measurable ROI, such as Rx cost savings and GLP-1 reductions.[1][2][3][4] The platform has shown validated outcomes like 1.93x ROI, high engagement rates, and NPS scores, earning the 2025 Health Value Award, with over $10M in funding fueling growth momentum including launches like the Pediatric Metabolic Program and Thrive longevity offering.[2][5][6]
Ciba Health was founded in 2020 by Dr. Innocent Clement, its CEO, in New York City, driven by a mission to address preventable chronic conditions like type 2 diabetes affecting one in ten Americans through root-cause approaches rather than reactive care.[1][4] Clement, a physician emphasizing precision health, built the company amid rising U.S. healthcare costs—86% tied to chronic diseases causing seven of ten deaths—leveraging AI/ML, advanced diagnostics, and virtual care to create integrated solutions.[3][4] Early traction came from enterprise partnerships with employers and health plans, validated clinical results, and expansions like the 2024 Pediatric Metabolic Program and Thrive platform launch, which offers 100+ labs (5x typical doctor panels) for direct-to-consumer access, marking pivotal moments in scaling beyond B2B to individual longevity.[4][6]
Ciba Health stands out in digital health through these key strengths:
Ciba Health rides the wave of AI-enabled precision medicine and value-based care, targeting the $4+ trillion U.S. healthcare market where chronic diseases drive 86% of costs amid GLP-1 drug booms and longevity trends like Blue Zones.[2][4] Timing is ideal post-2020 amid telehealth acceleration, wearable adoption, and employer demands for ROI-focused wellness, positioning it against competitors like Twin Health while influencing the ecosystem via validated models that cut pharmacy spend and extend clinical capacity.[1][2] By democratizing 5x advanced labs and root-cause insights through Thrive, it pushes payers and systems toward preventive, data-driven care, fostering a shift from reactive treatment to scalable reversal of metabolic epidemics.[3][4]
Ciba Health is poised for accelerated growth with its $10M+ funding, 2025 award, and expansions like Thrive and pediatrics, likely expanding partnerships and DTC adoption amid rising AI health tech demand.[2][5][6] Trends like multimodal AI diagnostics, GLP-1 optimization, and longevity focus will shape its path, potentially evolving it into a category leader influencing policy on chronic care costs. As chronic conditions strain systems, Ciba's root-cause platform—reversing diseases for healthier lives and lower spends—ties directly to its founding vision of transforming U.S. healthcare one personalized plan at a time.[1][4]
Ciba Health has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $10.0M Series A | DigiTx Partners, Esplanade HealthTech Ventures, OCA Ventures |